Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). The company employs its proprietary GEODe™ platform to engineer biologics capable of targeting GPCRs, a receptor family that accounts for more than 30 % of all approved drugs yet remains under‑served by biologic approaches. Its lead programs include TX45, an Fc‑relaxin fusion molecule intended for pulmonary hypertension associated with heart failure with preserved ejection fraction and related fibrotic conditions, and TX2100, a VHH‑Fc fusion antagonist antibody directed at the APJ receptor for the treatment of hereditary hemorrhagic telangiectasia. A third program seeks to create a bispecific GPCR modulator for fibrotic diseases, leveraging the GEODe™ technology to engage two complementary targets.

The company does not yet generate revenue from product sales, as it remains in the preclinical and clinical development stage. Financial support is obtained through equity transactions, such as the shares issued to Harvard College under the license agreement for the GEODe™ technology, and through collaboration agreements that fund research and development activities. No commercial product is currently marketed.

The company operates through the following segments.

Within the competitive biotechnology landscape, Tectonic Therapeutic differentiates itself by concentrating on biologic GPCR targets while many peers focus on small‑molecule drug discovery. Its competitive advantages stem from the GEODe™ platform, which enhances the success rate of antibody selection against challenging GPCRs, and from its deep expertise in membrane protein biochemistry that enables stable receptor conformations for naïve antibody libraries. The company faces competition from large pharmaceutical firms such as AstraZeneca, which is pursuing small‑molecule relaxin therapies for heart failure, and from specialized biotechs developing alternative approaches to hereditary hemorrhagic telangiectasia, including Diagonal Therapeutics (agonist antibodies), Alnylam Pharmaceuticals (RNAi‑based plasminogen reduction), Vaderis and Terremoto (small‑molecule AKT inhibitors), and Atavistik (kinase inhibitor programs). Additional rivals in the GPCR space include Septerna, SOSEI‑Heptares, Structure Therapeutics, Abalone Bio, Orion Biotechnology, Abilitia Bio, Confo Therapeutic, Omeros, and GPCR Therapeutics, each pursuing varying modalities ranging from small molecules to biologics.

The company’s prospective customers are patients suffering from conditions such as pulmonary hypertension associated with heart failure with preserved ejection fraction, pulmonary hypertension linked to interstitial lung disease, and hereditary hemorrhagic telangiectasia. In the nearer term, Tectonic Therapeutic collaborates with contract research organizations and manufacturers to advance its pipeline. Notably, it relies on WuXi Biologics for chemistry, manufacturing, and controls activities related to the TX45 program, and has engaged Novotech (Australia) Pty Limited under a master clinical contract services agreement for clinical trial execution and associated support functions.